Researchers in Prof. Michael Lin's laboratory have developed a viral-based cancer therapy platform that could be used for targeting treatment to cancer cells with aberrant signaling in EGFR or HER2 pathways.
Researchers at Stanford have developed methods of using CRISPR/Cas9-mediated genome editing to treat patients with EGFR-mutant non-small-cell lung cancer (NSCLC). Approximately 85% of lung cancers are NSCLC.